Skip to main content

Table 2 Multivariate Cox regression analysis of overall survival in each dataset

From: An integrated prognosis model of pharmacogenomic gene signature and clinical information for diffuse large B-cell lymphoma patients following CHOP-like chemotherapy

  Multivariate analysis
HR 95% CI p value
Training cohort
 GSE31312 (n = 449)
  Age 1.03 1.01–1.04 1.38 × 10−5
  Extra nodal sites number 1.20 1.03–1.41 2.37 × 10−2
  Stage 1.31 1.12–1.52 6.26 × 10−5
  ECOGa 1.41 1.21–1.64 7.33 × 10−6
  Resistance probability of doxorubicin 2.70 1.24–5.86 1.23 × 10−2
  Resistance probability of vincristine 1.28 0.61–2.70 0.51
Validating cohort
 GSE10846 (n = 342)
  Age 1.02 1.01–1.04 1.45 × 10−4
  Extra nodal sites number 0.99 0.80–1.22 0.95
  Stage 1.41 1.19–1.67 5.40 × 10−5
  ECOGa 1.59 1.32–1.91 6.43 × 10−7
  Resistance probability of doxorubicin 3.24 1.41–7.45 5.61 × 10−3
  Resistance probability of vincristine 1.40 0.61–3.23 0.43
  1. HR hazard ratio, 95% CI 95% confidence interval
  2. aThe Eastern Cooperative Oncology Group (ECOG) performance score ranges from 0 to 3, with a higher score indicating greater impairment